Genomic Health (GHDX) 27.34 $GHDX
Q1 Loss Wider than Expected at Genomic Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 2:30PM CDT
Following the disappointing earnings performance, Genomic Health's share price declined 1.5% on May 8.
Genomic Health Has Returned 15.1% Since SmarTrend Recommendation (GHDX)
Comtex SmarTrend(R) - Thu May 08, 11:07AM CDT
SmarTrend identified a Downtrend for Genomic Health (NASDAQ:GHDX) on January 27th, 2014 at $30.20. In approximately 3 months, Genomic Health has returned 15.13% as of today's recent price of $25.63.
Genomic Health Announces First Quarter 2014 Financial Results and Business Progress
PR Newswire - Tue May 06, 3:02PM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended March 31, 2014.
Genomic Health Announces Presentation of Multiple Oncotype DX® Studies in Breast, Prostate, Colon and Renal Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
PR Newswire - Mon May 05, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from nine studies of Oncotype DX® in breast, colon, prostate and renal cancer will be presented at the American Society of Clinical Oncology® (ASCO®) Annual Meeting, taking place May 30 - June 3, 2014 at McCormick Place in Chicago. New data, including two oral presentations, reinforce the company's successful approach to understanding tumor biology--now across four different cancer types--and highlight the following:
Oncotype DX® Changes Treatment Decisions in 45 Percent of Stage II Colon Cancer Patients
PR Newswire - Fri May 02, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced that The Oncologist published positive results from an Oncotype DX® colon cancer decision impact study, demonstrating that Recurrence Score® results changed treatment recommendations in 45 percent of stage II colon cancer patients. The study was conducted in collaboration with the Mayo Clinic Cancer Research Consortium.
Downtrend Call Working As Genomic Health Stock Falls 13.9% (GHDX)
Comtex SmarTrend(R) - Thu May 01, 9:55AM CDT
SmarTrend identified a Downtrend for Genomic Health (NASDAQ:GHDX) on January 27th, 2014 at $30.20. In approximately 3 months, Genomic Health has returned 13.89% as of today's recent price of $26.00.
Global & USA Cancer Biomarker Market Analysis 2014-2018
M2 - Thu May 01, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6wrk6/global_and_usa) has announced the addition of the "Global & USA Cancer Biomarker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends and Pipeline Analysis)" report to their offering. GLOBAL & USA CANCER BIOMARKER MARKET to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-development, Business Strategies, Industry Trends, and Pipeline Analysis) is a comprehensive report on the cancer biomarker industry and its impact on the health system. This report tackles the growing market interest in oncogenic biomarkers, personalized medicine, companion diagnostics and the associated market environment. Cancer biomarkers are molecular or genetic moieties (e.g., cells, proteins/peptides, genetic mutations, gene products, enzymes, or hormones) that not only are readily identifiable, but easily quantified in the lab setting. They function primarily to identify or correlate significantly with the severity or occurrence of a certain disease state. The rise in number of oncogenic biomarkers over the last number of years has massive potential in the healthcare industry and serves to propel both the personalized medicine and companion diagnostic markets. One of the most import aspects of biomarkers is their use to diagnose and assess the progress of disease states in patients. As quantitative markers, these agents also offer the ability to monitor response to certain drug treatments and so are important in the area of personalized medicine. Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics will be more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine will reduce the frequency of adverse drug reactions and therefore have a dramatic impact on health economics. Developmental and diagnostic companies will benefit from lower discovery and commercialization costs and more specific market subtypes. This report describes the current technologies that are propelling the cancer biomarker and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in the global market and the most developed market (US) are elucidated and analysed. This study reveals market figures of the overall biomarker market and the cancer biomarker space (2013-2018). Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. In summary, the cancer biomarker and associated companion diagnostic market have huge opportunities for growth. This industry will revolutionize the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics. Key Topics Covered: 1.0 Executive Summary 2.0 Global Burden of Cancer 3.0 Oncogenic Biomarkers - An Overview 4.0 Biomarker Validation 5.0 Current and Prospective Oncogenic Biomarkers 6.0 Cancer Biomarker Test Market Analysis 2013-2018 7.0 Oncology Biomarker Market Main Industry Players 8.0 Oncology Biomarker Market Products and Kits 9.0 Market Participant Financial and Business Strategy Analysis 10.0 Objective Business and Strategic Analysis of the Cancer Biomarker Market Companies Mentioned - 23andMe - Affymetrix - Ambry Genetics - Astex Pharmaceuticals - Atossa Genetics - BioMerieux - CuraGen - Celera Corporation (Quest Diagnostics) - Celldex Therapeutics - deCode Genetics (Amgen) - Foundation Medicine - Illumina - Genelex - Genomic Health - Myriad - Nodality - OriGene Technologies - Randox - Qiagen For more information visit http://www.researchandmarkets.com/research/j6...al_and_usa
Genomic Health to Announce First Quarter 2014 Financial Results and Host Conference Call on Tuesday, May 6, 2014
PR Newswire - Tue Apr 29, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, May 6 at 4:30 p.m. Eastern Time to discuss its first quarter 2014 financial results. The call and webcast will follow the release of the first quarter financial results after market close.
'Mad Money' Lightning Round: Stick With Baidu
at The Street - Sat Apr 26, 5:00AM CDT
Cramer thinks Genomic Health can go lower, doesn't like Molycorp but likes SandRidge Energy and its CEO.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Apr 25, 6:58PM CDT
Cramer is still watching earnings and the continuing crisis in Ukraine.
12.8% Return Seen to Date on SmarTrend Genomic Health Call (GHDX)
Comtex SmarTrend(R) - Thu Apr 24, 9:27AM CDT
SmarTrend identified a Downtrend for Genomic Health (NASDAQ:GHDX) on January 27th, 2014 at $30.20. In approximately 3 months, Genomic Health has returned 12.78% as of today's recent price of $26.34.
Global Adoption of Oncotype DX® Breast Cancer Test Continues to Grow with Achievement of Two Significant International Milestones
PR Newswire - Tue Apr 22, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced two important international milestones including additional reimbursement in Canada and the inclusion of the Oncotype DX® breast cancer test in major German clinical guidelines. In Canada, the BC Cancer Agency in British Columbia agreed to fund the Oncotype DX breast cancer test for eligible patients, expanding reimbursement to more than 80 percent of the country's population. In Germany, updated guidelines from the AGO (Gynecologic Oncology Working Group) now recommend the Oncotype DX breast cancer test as the only gene expression test to predict chemotherapy benefit in early-stage hormone receptor-positive invasive breast cancer.
British Columbia Breast Cancer Patients Gain Access to Oncotype DX® To Help Guide Chemotherapy Treatment Decisions
CNW Group - Tue Apr 22, 7:00AM CDT
Genomic Health's Test Now Available to Eligible Patients in the Province
Reimbursement for In Vitro Diagnostic (IVD) Tests
M2 - Wed Apr 16, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qlwp6x/reimbursement_for) has announced the addition of the "Reimbursement for In Vitro Diagnostic (IVD) Tests" report to their offering. The report studied some recent products and their success at the critical task of clearing payor standards and found that those with clinical studies backing up their effectiveness did far better. The finding was made in its new research report on the topic, Reimbursement for IVD Tests. In the United States, the Centers for Medicare and Medicaid Services (CMS) determines and implements payment methodologies for specific types of healthcare services covered by Medicare and Medicaid. These federal plans, which combined cover almost 100 million persons, represent the largest health care plans in the nation by a wide margin and thus most other public and private health plans defer to CMS regarding coverage decisions. Decision-makers focus on cost-savings, according to analysis, and reward products that save the healthcare system money and prove results. This is not easy for IVD products, but some form of trial is the preferred way. While randomized controlled trials remain the preferred study design for establishing the causal effects of medical interventions on patient outcomes, other study designs can sometimes substitute for them, particularly in the evaluation of diagnostic products. Well-designed, non-randomized observational studies like patient cohort studies, case control studies, registries, and surveillance studies may all provide evidence that is sufficiently strong to inform payers making coverage and payment determinations. The report cites three examples of test products that obtained reimbursement status: - AlloMap Developed by privately held XDx Inc., is thus far the only non-invasive gene expression test that assists physicians in identifying the absence of heart transplant rejection. - Agendia's MammaPrint test for lymph node negative breast cancer patients is used to estimate a woman's recurrence risk for early-stage (Stage I or II) breast cancer, and can help patients and physicians make a more informed decision about whether to use chemotherapy to reduce recurrence risk. - OncotypeDX, developed by publicly traded Genomic Health and introduced in 2004, quantifies the likelihood of disease recurrence in women with early-stage ER positive breast cancer and assesses the likely benefit from certain types of chemotherapy. In all cases these products were able to demonstrate effectiveness in clinical studies and that they produced cost-savings over other test products or in reduction of treatment costs. Reimbursement for IVD Tests contains detailed case studies of successful products, a complete explanation of the reimbursement process, statistics and relevant codes. Key Topics Covered: Chapter One: Executive Summary Chapter Two: CMS And Private Insurance Reimbursement Chapter Three: Important Issues In IVD Reimbursement Chapter Four: Case Studies In Obtaining For more information visit http://www.researchandmarkets.com/research/ql...sement_for
The Global Market for Biomarkers: Concise Analysis of the $25 Billion Industry
M2 - Tue Apr 15, 9:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r7r264/the_global_market) has announced the addition of the "The Global Market for Biomarkers: Cancer Markers, Cardiac Markers, Blood Markers, Endocrine Markers, Infectious Disease and Neurological Disease Markers" report to their offering. The global medical biomarker market is valued at about $25.9 billion for 2013, an increase of 10.2% since last year. Many biomarkers are now successfully marketed with several of them part of a routine diagnostic and treatment plan, with new products in the pipeline. Biomarkers are anatomic, physiologic, genetic, biochemical or molecular parameters. Biomarkers are detectable and measureable by a variety of methods including laboratory assays and medical imaging. Each biomarker is characteristic as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. An example is creatine kinase, or CK-MB, a marker that facilitates high-energy phosphates in the body's tissues, and can suggest a cardiovascular event when levels are high. The cancer biomarker, or tumor marker, market is one of the more advanced segments with viable products, and currently the largest segment, according to the report. The report says the majority of competitive participation for medical biomarkers is in the United States and Europe. However, competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas such as Asia and Latin America. There are numerous companies in the market, including multiproduct companies such as Abbott and Roche, as well as small niche developers, such as 20/20 GeneSystems, CardioDx or MemoryDx. Key Topics Covered: Chapter One: Executive Summary Chapter Two: Introduction To The Medical Biomarkers Industry Chapter Three: Industry Trends Chapter Four: Biomarkers In Cancer Chapter Five: Biomarkers In Cardiovascular Disease And Blood Disorders Chapter Six: Biomarkers In Endocrine And Immune Disorders Chapter Seven: Biomarkers In Infectious Disease Chapter Eight: Biomarkers In Nervous System Disorders Chapter Nine: Market Summary Chapter Ten: Company Profiles - 20/20 GeneSystems - Abbott Laboratories - Affymetrix - Agendia - Alere - Beckman Coulter - Becton Dickinson - Biocartis SA - Biodesix - bioMerieux - BioReference Laboratory - bioTheranostics - CardioDX - Celera Alameda - Clarient - deCODE Genetics - DiaGenic - Genomic Health - Johnson & Johnson - Life Techologies - Memory Dx - Myriad Genetics - Nanostring Technologies - OPKO Health - Provista Dx - Qiagen - Roche - Seimens Healthcare - Tethys Bioscience - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/r7...bal_market
Clinical Laboratory Services Market 2013-2018: Markets, Growth Opportunities, Competitive Analysis and Competitor Profiles
M2 - Tue Apr 15, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d98zpd/clinical) has announced the addition of the "Clinical Laboratory Services - Markets, Growth Opportunities, Competitive Analysis and Competitor Profiles" report to their offering. The Clinical Laboratory Services estimates the market at $99.1 billion for 2013, up 1.3% from the estimated value in 2008 of $92.7 billion. Faced with daunting reimbursement cuts and other challenges, the world market for clinical laboratory services grew just over one percent in the past five year. The report notes that while there are a number of drivers for this market: aging populations, a growing incidence of chronic diseases, increasing emphasis on diagnosis and disease monitoring, and a growth in advanced testing technologies and practices. However, there are also a number of inhibitors to growth such as the growing emphasis to reduce health costs and uncertain economic conditions, and these are dampening growth. In the United States, the U.S. Congress ultimately has the responsibility to adjust the Medicare fee schedule according to economic factors, including controlling costs, monitoring utilization, and ensuring adequate delivery of health care services. The passing of the Patient Protection and Affordable Care Act generated a number of provisions on laboratory fee schedules, mostly in the direction of reductions. These reductions were effective starting 2011 and will continue to be adjusted through 2015. Medicare has slashed reimbursement amounts for many common tests such as Vitamin B12, triglycerides and glucose nearly six percent between 2009 and 2013. Some tests, such as total iron or aluminum tests have been cut 19% and 30% respectively during that period. Bio-Reference Laboratories, Quest, Lab Corp, Myriad, and Spectra are among the leaders in the industry. Quest Diagnostics and LabCorp have advantages in the market due to the wide exposure, large number of locations, and greater financial positions. Smaller, independent laboratories may find it difficult to keep up with the fast changing industry largely due to limited financial abilities to invest in new technologies and testing services. Some laboratories, such as Bio-Reference Labs have found success in operating on a regional basis while companies such as Myriad Genetics and Genomic Health remain competitive by focusing on more specialized genetic-based testing. Key Topics Covered: 1. Executive Summary 2. Industry Overview 3. CLIA Laboratory Registration, Laboratories By Type 4. Leading Market Participants 5. Market Trends And Summary Companies Mentioned - Bio-Reference Laboratories - Clarient, Inc. - DaVita - Genomic Health - Genoptix, Inc. - Genzyme Corporation - Laboratory Corporation of America (LabCorp) - Quest Diagnostics, Inc. - Spectra Laboratories For more information visit http://www.researchandmarkets.com/research/d98zpd/clinical
Invitae's Multi-Gene Panels Can Provide Clinical Benefit to Patients Seeking Hereditary Cancer Risk Assessment
Business Wire - Mon Apr 14, 3:00PM CDT
Invitae Corporation, a genetic information company, today announced the publication of initial data from its research collaboration with Stanford University in the Journal of Clinical Oncology, published online on April 14. The study demonstrates that multi-gene hereditary cancer panels can offer comparable performance to traditional BRCA1/2 genetic testing and can provide additional clinical benefit to doctors and patients seeking cancer risk assessment.
Balanced View on Genomic Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 2:20PM CDT
On Apr 4, we issued an updated research report on Genomic Health.
Genomic Health Down 13.6% Since SmarTrend Downtrend Call (GHDX)
Comtex SmarTrend(R) - Thu Apr 03, 10:02AM CDT
SmarTrend identified a Downtrend for Genomic Health (NASDAQ:GHDX) on January 27th, 2014 at $30.20. In approximately 2 months, Genomic Health has returned 13.61% as of today's recent price of $26.09.
Q1 Loss Wider than Expected at Genomic Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 2:30PM CDT
Following the disappointing earnings performance, Genomic Health's share price declined 1.5% on May 8.
Genomic Health Has Returned 15.1% Since SmarTrend Recommendation (GHDX)
Comtex SmarTrend(R) - Thu May 08, 11:07AM CDT
SmarTrend identified a Downtrend for Genomic Health (NASDAQ:GHDX) on January 27th, 2014 at $30.20. In approximately 3 months, Genomic Health has returned 15.13% as of today's recent price of $25.63.
Genomic Health Announces First Quarter 2014 Financial Results and Business Progress
PR Newswire - Tue May 06, 3:02PM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended March 31, 2014.
Genomic Health Announces Presentation of Multiple Oncotype DX® Studies in Breast, Prostate, Colon and Renal Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
PR Newswire - Mon May 05, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from nine studies of Oncotype DX® in breast, colon, prostate and renal cancer will be presented at the American Society of Clinical Oncology® (ASCO®) Annual Meeting, taking place May 30 - June 3, 2014 at McCormick Place in Chicago. New data, including two oral presentations, reinforce the company's successful approach to understanding tumor biology--now across four different cancer types--and highlight the following:
Oncotype DX® Changes Treatment Decisions in 45 Percent of Stage II Colon Cancer Patients
PR Newswire - Fri May 02, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced that The Oncologist published positive results from an Oncotype DX® colon cancer decision impact study, demonstrating that Recurrence Score® results changed treatment recommendations in 45 percent of stage II colon cancer patients. The study was conducted in collaboration with the Mayo Clinic Cancer Research Consortium.
Downtrend Call Working As Genomic Health Stock Falls 13.9% (GHDX)
Comtex SmarTrend(R) - Thu May 01, 9:55AM CDT
SmarTrend identified a Downtrend for Genomic Health (NASDAQ:GHDX) on January 27th, 2014 at $30.20. In approximately 3 months, Genomic Health has returned 13.89% as of today's recent price of $26.00.
Global & USA Cancer Biomarker Market Analysis 2014-2018
M2 - Thu May 01, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6wrk6/global_and_usa) has announced the addition of the "Global & USA Cancer Biomarker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends and Pipeline Analysis)" report to their offering. GLOBAL & USA CANCER BIOMARKER MARKET to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-development, Business Strategies, Industry Trends, and Pipeline Analysis) is a comprehensive report on the cancer biomarker industry and its impact on the health system. This report tackles the growing market interest in oncogenic biomarkers, personalized medicine, companion diagnostics and the associated market environment. Cancer biomarkers are molecular or genetic moieties (e.g., cells, proteins/peptides, genetic mutations, gene products, enzymes, or hormones) that not only are readily identifiable, but easily quantified in the lab setting. They function primarily to identify or correlate significantly with the severity or occurrence of a certain disease state. The rise in number of oncogenic biomarkers over the last number of years has massive potential in the healthcare industry and serves to propel both the personalized medicine and companion diagnostic markets. One of the most import aspects of biomarkers is their use to diagnose and assess the progress of disease states in patients. As quantitative markers, these agents also offer the ability to monitor response to certain drug treatments and so are important in the area of personalized medicine. Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics will be more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine will reduce the frequency of adverse drug reactions and therefore have a dramatic impact on health economics. Developmental and diagnostic companies will benefit from lower discovery and commercialization costs and more specific market subtypes. This report describes the current technologies that are propelling the cancer biomarker and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in the global market and the most developed market (US) are elucidated and analysed. This study reveals market figures of the overall biomarker market and the cancer biomarker space (2013-2018). Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. In summary, the cancer biomarker and associated companion diagnostic market have huge opportunities for growth. This industry will revolutionize the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics. Key Topics Covered: 1.0 Executive Summary 2.0 Global Burden of Cancer 3.0 Oncogenic Biomarkers - An Overview 4.0 Biomarker Validation 5.0 Current and Prospective Oncogenic Biomarkers 6.0 Cancer Biomarker Test Market Analysis 2013-2018 7.0 Oncology Biomarker Market Main Industry Players 8.0 Oncology Biomarker Market Products and Kits 9.0 Market Participant Financial and Business Strategy Analysis 10.0 Objective Business and Strategic Analysis of the Cancer Biomarker Market Companies Mentioned - 23andMe - Affymetrix - Ambry Genetics - Astex Pharmaceuticals - Atossa Genetics - BioMerieux - CuraGen - Celera Corporation (Quest Diagnostics) - Celldex Therapeutics - deCode Genetics (Amgen) - Foundation Medicine - Illumina - Genelex - Genomic Health - Myriad - Nodality - OriGene Technologies - Randox - Qiagen For more information visit http://www.researchandmarkets.com/research/j6...al_and_usa
Genomic Health to Announce First Quarter 2014 Financial Results and Host Conference Call on Tuesday, May 6, 2014
PR Newswire - Tue Apr 29, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, May 6 at 4:30 p.m. Eastern Time to discuss its first quarter 2014 financial results. The call and webcast will follow the release of the first quarter financial results after market close.
'Mad Money' Lightning Round: Stick With Baidu
at The Street - Sat Apr 26, 5:00AM CDT
Cramer thinks Genomic Health can go lower, doesn't like Molycorp but likes SandRidge Energy and its CEO.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Apr 25, 6:58PM CDT
Cramer is still watching earnings and the continuing crisis in Ukraine.
12.8% Return Seen to Date on SmarTrend Genomic Health Call (GHDX)
Comtex SmarTrend(R) - Thu Apr 24, 9:27AM CDT
SmarTrend identified a Downtrend for Genomic Health (NASDAQ:GHDX) on January 27th, 2014 at $30.20. In approximately 3 months, Genomic Health has returned 12.78% as of today's recent price of $26.34.
Global Adoption of Oncotype DX® Breast Cancer Test Continues to Grow with Achievement of Two Significant International Milestones
PR Newswire - Tue Apr 22, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced two important international milestones including additional reimbursement in Canada and the inclusion of the Oncotype DX® breast cancer test in major German clinical guidelines. In Canada, the BC Cancer Agency in British Columbia agreed to fund the Oncotype DX breast cancer test for eligible patients, expanding reimbursement to more than 80 percent of the country's population. In Germany, updated guidelines from the AGO (Gynecologic Oncology Working Group) now recommend the Oncotype DX breast cancer test as the only gene expression test to predict chemotherapy benefit in early-stage hormone receptor-positive invasive breast cancer.
British Columbia Breast Cancer Patients Gain Access to Oncotype DX® To Help Guide Chemotherapy Treatment Decisions
CNW Group - Tue Apr 22, 7:00AM CDT
Genomic Health's Test Now Available to Eligible Patients in the Province
Reimbursement for In Vitro Diagnostic (IVD) Tests
M2 - Wed Apr 16, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qlwp6x/reimbursement_for) has announced the addition of the "Reimbursement for In Vitro Diagnostic (IVD) Tests" report to their offering. The report studied some recent products and their success at the critical task of clearing payor standards and found that those with clinical studies backing up their effectiveness did far better. The finding was made in its new research report on the topic, Reimbursement for IVD Tests. In the United States, the Centers for Medicare and Medicaid Services (CMS) determines and implements payment methodologies for specific types of healthcare services covered by Medicare and Medicaid. These federal plans, which combined cover almost 100 million persons, represent the largest health care plans in the nation by a wide margin and thus most other public and private health plans defer to CMS regarding coverage decisions. Decision-makers focus on cost-savings, according to analysis, and reward products that save the healthcare system money and prove results. This is not easy for IVD products, but some form of trial is the preferred way. While randomized controlled trials remain the preferred study design for establishing the causal effects of medical interventions on patient outcomes, other study designs can sometimes substitute for them, particularly in the evaluation of diagnostic products. Well-designed, non-randomized observational studies like patient cohort studies, case control studies, registries, and surveillance studies may all provide evidence that is sufficiently strong to inform payers making coverage and payment determinations. The report cites three examples of test products that obtained reimbursement status: - AlloMap Developed by privately held XDx Inc., is thus far the only non-invasive gene expression test that assists physicians in identifying the absence of heart transplant rejection. - Agendia's MammaPrint test for lymph node negative breast cancer patients is used to estimate a woman's recurrence risk for early-stage (Stage I or II) breast cancer, and can help patients and physicians make a more informed decision about whether to use chemotherapy to reduce recurrence risk. - OncotypeDX, developed by publicly traded Genomic Health and introduced in 2004, quantifies the likelihood of disease recurrence in women with early-stage ER positive breast cancer and assesses the likely benefit from certain types of chemotherapy. In all cases these products were able to demonstrate effectiveness in clinical studies and that they produced cost-savings over other test products or in reduction of treatment costs. Reimbursement for IVD Tests contains detailed case studies of successful products, a complete explanation of the reimbursement process, statistics and relevant codes. Key Topics Covered: Chapter One: Executive Summary Chapter Two: CMS And Private Insurance Reimbursement Chapter Three: Important Issues In IVD Reimbursement Chapter Four: Case Studies In Obtaining For more information visit http://www.researchandmarkets.com/research/ql...sement_for
The Global Market for Biomarkers: Concise Analysis of the $25 Billion Industry
M2 - Tue Apr 15, 9:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r7r264/the_global_market) has announced the addition of the "The Global Market for Biomarkers: Cancer Markers, Cardiac Markers, Blood Markers, Endocrine Markers, Infectious Disease and Neurological Disease Markers" report to their offering. The global medical biomarker market is valued at about $25.9 billion for 2013, an increase of 10.2% since last year. Many biomarkers are now successfully marketed with several of them part of a routine diagnostic and treatment plan, with new products in the pipeline. Biomarkers are anatomic, physiologic, genetic, biochemical or molecular parameters. Biomarkers are detectable and measureable by a variety of methods including laboratory assays and medical imaging. Each biomarker is characteristic as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. An example is creatine kinase, or CK-MB, a marker that facilitates high-energy phosphates in the body's tissues, and can suggest a cardiovascular event when levels are high. The cancer biomarker, or tumor marker, market is one of the more advanced segments with viable products, and currently the largest segment, according to the report. The report says the majority of competitive participation for medical biomarkers is in the United States and Europe. However, competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas such as Asia and Latin America. There are numerous companies in the market, including multiproduct companies such as Abbott and Roche, as well as small niche developers, such as 20/20 GeneSystems, CardioDx or MemoryDx. Key Topics Covered: Chapter One: Executive Summary Chapter Two: Introduction To The Medical Biomarkers Industry Chapter Three: Industry Trends Chapter Four: Biomarkers In Cancer Chapter Five: Biomarkers In Cardiovascular Disease And Blood Disorders Chapter Six: Biomarkers In Endocrine And Immune Disorders Chapter Seven: Biomarkers In Infectious Disease Chapter Eight: Biomarkers In Nervous System Disorders Chapter Nine: Market Summary Chapter Ten: Company Profiles - 20/20 GeneSystems - Abbott Laboratories - Affymetrix - Agendia - Alere - Beckman Coulter - Becton Dickinson - Biocartis SA - Biodesix - bioMerieux - BioReference Laboratory - bioTheranostics - CardioDX - Celera Alameda - Clarient - deCODE Genetics - DiaGenic - Genomic Health - Johnson & Johnson - Life Techologies - Memory Dx - Myriad Genetics - Nanostring Technologies - OPKO Health - Provista Dx - Qiagen - Roche - Seimens Healthcare - Tethys Bioscience - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/r7...bal_market
Clinical Laboratory Services Market 2013-2018: Markets, Growth Opportunities, Competitive Analysis and Competitor Profiles
M2 - Tue Apr 15, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d98zpd/clinical) has announced the addition of the "Clinical Laboratory Services - Markets, Growth Opportunities, Competitive Analysis and Competitor Profiles" report to their offering. The Clinical Laboratory Services estimates the market at $99.1 billion for 2013, up 1.3% from the estimated value in 2008 of $92.7 billion. Faced with daunting reimbursement cuts and other challenges, the world market for clinical laboratory services grew just over one percent in the past five year. The report notes that while there are a number of drivers for this market: aging populations, a growing incidence of chronic diseases, increasing emphasis on diagnosis and disease monitoring, and a growth in advanced testing technologies and practices. However, there are also a number of inhibitors to growth such as the growing emphasis to reduce health costs and uncertain economic conditions, and these are dampening growth. In the United States, the U.S. Congress ultimately has the responsibility to adjust the Medicare fee schedule according to economic factors, including controlling costs, monitoring utilization, and ensuring adequate delivery of health care services. The passing of the Patient Protection and Affordable Care Act generated a number of provisions on laboratory fee schedules, mostly in the direction of reductions. These reductions were effective starting 2011 and will continue to be adjusted through 2015. Medicare has slashed reimbursement amounts for many common tests such as Vitamin B12, triglycerides and glucose nearly six percent between 2009 and 2013. Some tests, such as total iron or aluminum tests have been cut 19% and 30% respectively during that period. Bio-Reference Laboratories, Quest, Lab Corp, Myriad, and Spectra are among the leaders in the industry. Quest Diagnostics and LabCorp have advantages in the market due to the wide exposure, large number of locations, and greater financial positions. Smaller, independent laboratories may find it difficult to keep up with the fast changing industry largely due to limited financial abilities to invest in new technologies and testing services. Some laboratories, such as Bio-Reference Labs have found success in operating on a regional basis while companies such as Myriad Genetics and Genomic Health remain competitive by focusing on more specialized genetic-based testing. Key Topics Covered: 1. Executive Summary 2. Industry Overview 3. CLIA Laboratory Registration, Laboratories By Type 4. Leading Market Participants 5. Market Trends And Summary Companies Mentioned - Bio-Reference Laboratories - Clarient, Inc. - DaVita - Genomic Health - Genoptix, Inc. - Genzyme Corporation - Laboratory Corporation of America (LabCorp) - Quest Diagnostics, Inc. - Spectra Laboratories For more information visit http://www.researchandmarkets.com/research/d98zpd/clinical
Invitae's Multi-Gene Panels Can Provide Clinical Benefit to Patients Seeking Hereditary Cancer Risk Assessment
Business Wire - Mon Apr 14, 3:00PM CDT
Invitae Corporation, a genetic information company, today announced the publication of initial data from its research collaboration with Stanford University in the Journal of Clinical Oncology, published online on April 14. The study demonstrates that multi-gene hereditary cancer panels can offer comparable performance to traditional BRCA1/2 genetic testing and can provide additional clinical benefit to doctors and patients seeking cancer risk assessment.
Balanced View on Genomic Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 2:20PM CDT
On Apr 4, we issued an updated research report on Genomic Health.
Genomic Health Down 13.6% Since SmarTrend Downtrend Call (GHDX)
Comtex SmarTrend(R) - Thu Apr 03, 10:02AM CDT
SmarTrend identified a Downtrend for Genomic Health (NASDAQ:GHDX) on January 27th, 2014 at $30.20. In approximately 2 months, Genomic Health has returned 13.61% as of today's recent price of $26.09.
